Will your evidence survive the JCA?
Sur Access helps emerging biotech get EU and Swiss market access right — before the Joint Clinical Assessment decides your price, and your valuation. Evidence strategy, JCA readiness, and the numbers that follow.
F E A T U R E S
A strong FDA story is no longer enough.
Bridging the gap between scientific innovation and commercial value.
Since 2025, Europe's Joint Clinical Assessment (JCA) has become the real gatekeeper for premium pricing — and under Most-Favored-Nation pressure, a weak European assessment now drags down the US price floor too. For an emerging biotech, an asset that looks like a blockbuster on FDA potential can lose most of its value if the evidence doesn't hold up to the JCA. That risk is fixable — but only while there's still time to act on it.
Built for emerging biotech — not the big-pharma machine
Roche and Novartis have floors of in-house HTA specialists. You don't, and you don't need them full-time. I'm the specialist you bring in for the questions that decide your value:
- Will your trial win a strong added-benefit rating?
- What price will it actually command across the EU-5?
- What is the asset really worth once JCA and MFN are priced in?
I connect the evidence to the value — the piece that your strategy cannot miss.
How we do it:
Evidence Audit
The Problem: VCs buy assets based on FDA potential. But in 2026, the EU JCA (Joint Clinical Assessment) is the true gatekeeper. A "Scientific Blockbuster" can fail commercially if its trial design doesn't meet the JCA's stringent evidence quality standards.
Our Added Value: We perform a Subject Matter Expert (SME) Audit of the clinical protocol. We ensure the evidence quality is high enough to secure the final "Grade-A" rating required for premium pricing in the EU-4 (Germany, France, Italy, Spain).
Planning Strategy
The Problem: US biotechs design for a "global average." The JCA demands comparisons against 27 different local treatment guidelines (PICOs).
Our Added Value: We identify "Evidence Gaps" while there is still time to fix them. We map the trial design against the most important EU national treatment guidelines to ensure the asset isn't "commercially stranded" at launch.
EU "Spillover" Defense
The Problem: Under the 2025 MFN Executive Order, a low price in Europe—caused by a poor JCA assessment—now erodes the US price floor.
Our Added Value: We protect the US revenue by winning the Evidence Strategy in Europe. We verify that the European reimbursement potential is robust enough to prevent a "Spillover" that would trigger a 40% rNPV haircut.
Strategic Execution: Switzerland & Beyond
While our strategy is global, our execution is local. We leverage deep expertise in premium launch markets to set strategic value anchors.
- Swiss Premium Access: Mastering the world’s most sophisticated semi-confidential P&R environment to set a strong global reference price.
- CEE Gateway Strategy: Utilizing local Croatian expertise to set regional precedents and optimize budget impact for Eastern European entry.
Our Partners Trust Our Approach
